These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 17992686)

  • 1. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users.
    McCann UD; Kuwabara H; Kumar A; Palermo M; Abbey R; Brasic J; Ye W; Alexander M; Dannals RF; Wong DF; Ricaurte GA
    Synapse; 2008 Feb; 62(2):91-100. PubMed ID: 17992686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428.
    McCann UD; Wong DF; Yokoi F; Villemagne V; Dannals RF; Ricaurte GA
    J Neurosci; 1998 Oct; 18(20):8417-22. PubMed ID: 9763484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.
    Johanson CE; Frey KA; Lundahl LH; Keenan P; Lockhart N; Roll J; Galloway GP; Koeppe RA; Kilbourn MR; Robbins T; Schuster CR
    Psychopharmacology (Berl); 2006 Apr; 185(3):327-38. PubMed ID: 16518646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.
    Boileau I; McCluskey T; Tong J; Furukawa Y; Houle S; Kish SJ
    Neuropsychopharmacology; 2016 Mar; 41(4):1179-87. PubMed ID: 26321315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of striatal dopamine transporter levels in chronic heroin-dependent and methamphetamine-dependent subjects.
    Yuan J; Liu XD; Han M; Lv RB; Wang YK; Zhang GM; Li Y
    Addict Biol; 2017 Jan; 22(1):229-234. PubMed ID: 26040446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.
    McCann UD; Szabo Z; Vranesic M; Palermo M; Mathews WB; Ravert HT; Dannals RF; Ricaurte GA
    Psychopharmacology (Berl); 2008 Oct; 200(3):439-50. PubMed ID: 18661256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
    Melega WP; Lacan G; Desalles AA; Phelps ME
    Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study.
    Chou YH; Huang WS; Su TP; Lu RB; Wan FJ; Fu YK
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):46-52. PubMed ID: 16842981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence.
    Wang GJ; Volkow ND; Chang L; Miller E; Sedler M; Hitzemann R; Zhu W; Logan J; Ma Y; Fowler JS
    Am J Psychiatry; 2004 Feb; 161(2):242-8. PubMed ID: 14754772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased dopamine activity predicts relapse in methamphetamine abusers.
    Wang GJ; Smith L; Volkow ND; Telang F; Logan J; Tomasi D; Wong CT; Hoffman W; Jayne M; Alia-Klein N; Thanos P; Fowler JS
    Mol Psychiatry; 2012 Sep; 17(9):918-25. PubMed ID: 21747399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine.
    Bjorklund NL; Sorg BA; Schenk JO
    Synapse; 2008 Oct; 62(10):736-45. PubMed ID: 18651643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.
    O'Neil ML; Kuczenski R; Segal DS; Cho AK; Lacan G; Melega WP
    Synapse; 2006 Nov; 60(6):465-73. PubMed ID: 16897726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence.
    Yuan J; Lv R; Robert Brašić J; Han M; Liu X; Wang Y; Zhang G; Liu C; Li Y; Deng Y
    Psychiatry Res; 2014 Jan; 221(1):92-6. PubMed ID: 24314908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism.
    Baucum AJ; Rau KS; Riddle EL; Hanson GR; Fleckenstein AE
    J Neurosci; 2004 Mar; 24(13):3436-43. PubMed ID: 15056723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release.
    Volkow ND; Wang GJ; Smith L; Fowler JS; Telang F; Logan J; Tomasi D
    Neuroimage; 2015 Nov; 121():20-8. PubMed ID: 26208874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Striatal Dopamine D2-type Receptor Availability is Linked to Simulated Drug Choice in Methamphetamine Users.
    Moeller SJ; Okita K; Robertson CL; Ballard ME; Konova AB; Goldstein RZ; Mandelkern MA; London ED
    Neuropsychopharmacology; 2018 Mar; 43(4):751-760. PubMed ID: 28664927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
    McFadden LM; Hadlock GC; Allen SC; Vieira-Brock PL; Stout KA; Ellis JD; Hoonakker AJ; Andrenyak DM; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles.
    Melega WP; Jorgensen MJ; Laćan G; Way BM; Pham J; Morton G; Cho AK; Fairbanks LA
    Neuropsychopharmacology; 2008 May; 33(6):1441-52. PubMed ID: 17625500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users.
    Chen CK; Lin SK; Chen YC; Huang MC; Chen TT; Ree SC; Wang LJ
    Drug Alcohol Depend; 2015 Mar; 148():158-64. PubMed ID: 25601645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations.
    Villemagne V; Yuan J; Wong DF; Dannals RF; Hatzidimitriou G; Mathews WB; Ravert HT; Musachio J; McCann UD; Ricaurte GA
    J Neurosci; 1998 Jan; 18(1):419-27. PubMed ID: 9412518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.